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Kinase regulationProtein structure determination of soluble globular protein domains has developed into an efﬁcient routine
technology which can now be applied to generate and analyze structures of entire human protein families. In
the kinase area, several kinase families still lack comprehensive structural analysis. Nevertheless, Structural
Genomics (SG) efforts contributed more than 40 kinase catalytic domain structures during the past 4 years
providing a rich resource of information for large scale comparisons of kinase active sites. Moreover, many of
the released structures are inhibitor complexes that offer chemical starting points for development of
selective and potent inhibitors. Here we discuss the currently available structural data and strategies that can
be utilized for the development of highly selective inhibitors.
© 2009 Elsevier B.V. Open access under CC BY license.1. Introduction
Protein phosphorylation is fundamental to all aspects of cell
organization and behaviour. The interplay of 518 human kinases and
the phosphatase family creates a signalling network that controls
most signalling processes through reversible phosphorylation [1].
Malfunction of kinases has been identiﬁed as a common mechanism
for many diseases including cancer, inﬂammation, infection and
neurodegeneration [2]. Accordingly, kinase inhibitor development has
been one of the major focuses of drug development during the past
two decades [3–5], a considerable effort that led to the approval of
8 low molecular weight drugs so far. However, due to tremendous
difﬁculties in developing highly selective inhibitors, most kinome
targeted drug development programs restrict application to the
oncology area [6]. Indeed, recent developments of screening plat-
forms that cover most human kinases revealed that many currently
used inhibitors inhibit several largely diverse kinases suggesting that
cross reactivity of kinases is difﬁcult to predict. Here, we discuss how
the large-scale structural determination and small molecule screening
efforts contribute towards understanding of phosphorylation depen-
dent signalling in general and kinome targeted drug development.
Eukaryotic protein kinase domains (ePKs) possess highly con-
served architecture comprising an N-terminal lobe with the con-
served regulatory helix αC, and a larger mainly α-helical C-terminalat tel.: +44 1865 617580; fax:
x: +44 1865 617575.
Eswaran),
 license.lobe (Fig. 1A). The active site is located at the interface between the
two kinase lobes and contains a number of highly conserved motifs
that are essential for catalytic activity. Key catalytic motifs include the
ATP/Mg2+ binding motifs “VIAK” and “DFG,” the catalytic HRD motif
and the activation segment. A large number of kinases are activated by
phosphorylation of the activation segment which is typically
disordered in its inactive state and assumes a stable structure suitable
for substrate binding in its phosphorylated active state [7–9].
2. The human kinome: current structural coverage
Currently there are 136 unique human catalytic domain structures
(26% of all kinases) in the protein databank (PDB) (Fig. 1). However,
the structural knowledge is not equally distributed and for many
kinase groups there are only few structural models available [10]. In
addition, a large fraction of kinases share less than 30% sequence
homology with the closest related target of known structure.
Moreover, the diversity of regulatory mechanisms that have been
unravelled by structural studies makes this protein family still a very
interesting target for structural investigations. The complex regulatory
mechanisms of kinases that often differ even between closely related
proteins are also the main reason why despite the large number of
known kinase structures academic structural chemistry laboratories
did not loose interest in kinases and continue to contribute about
8 novel kinase structures per year (Fig. 1B). Structural genomics efforts
released 48 new human kinase structures so far and therefore
contributed signiﬁcantly to the available structural knowledge of
this protein family. However, even with the current rate of structure
determination itwill still takemore than 2 decades untilwewill have a
Fig. 1. Kinase architecture and available structural knowledge. (A) Kinase domain organization and structural elements that regulate kinase activity. The upper and lower lobe of the
kinase catalytic domain is highlighted in yellow and green, respectively. Elements important for catalytic activity are highlighted and labelled. (B) Release of new kinase structures
into the protein data bank (http://www.rcsb.org/pdb/home/home.do) by academic (red), industrial (green) and structural genomics groups (blue). Shown are only human crystal
structures considering the date when the structure has been released for the ﬁrst time. (C) Available crystal structures of kinase catalytic domains mapped onto the phylogenetic tree
of the human kinome [38].
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in this area is monitored on the SGC website (http://www.sgc.ox.ac.
uk/research/kinases/) and other resources [11].
3. Contribution of SG for our understanding of kinase regulation
Structural comparison is a powerful method for the identiﬁcation
of new mechanisms underlying enzymatic regulation. However,
structural features may be inﬂuenced by the crystalline state of the
protein. High throughput technologies offer the possibility to generate
several structures of the same protein or closely related isozymes that
differ in crystal contact regions adding conﬁdence to the interpreta-
tion of structural data. For instance, regulation of kinase autopho-
sphorylation by activation segment exchange between two adjacent
catalytic domains was initially observed in the crystal structure of the
kinase CHK2 [12]. Subsequent analysis of structures released by SG
revealed that this mechanism being conserved quite widely in kinases
that autophosphorylate at non-consensus sites located in the
activation segment establishing this structural feature as a general
mechanism of regulation [13,14]. Structures of different conforma-
tional states that are populated during catalysis can be generated
using different inhibitors. Kinase inhibitors often recognize a certain
conformation of a kinase and stabilize this state during crystallization.
For the family of p21 activating kinases (PAKs) the combination of
closely related isozymes and different inhibitors revealed the
conformational states that are likely to be adopted during catalysis
[15]. Comparison of different PAK crystal structures showed that helix
αC, a key regulatory element of kinase function, extended its helical
structure by one turn at the N-terminus. The observed structuralchanges led to the formation of interactions between conserved
residues which structurally link the glycine rich loop, αC and the
activation segment and anchorαC in an active conformation. Multiple
crystal structures revealed also the role of the SH2 domain in
maintaining the active state of the tyrosine kinase Fes [16]. SG efforts
on unusual kinase that lie at the center of the kinome tree revealed
new architectures of regulatory elements and identiﬁed a novel
structural organization of activation segments in MPSK1 [17] and the
atypical kinase haspin [18]. Also the ﬁrst truly inactive pseudokinase,
VRK3, has been released by SG efforts. Comparison with the closely
related active isoform VRK2 showed that VRK3 stabilizes a pseudoac-
tive conformation by mimicking an ATP bound state by acidic
residues. The observed alterations in the kinase active site generated
a structure with an inaccessible electronegative active site that is
catalytically inert and can serve as a stable platform for the
recruitment of interaction partners [19]. Thus, the structural studies
led to a deeper understanding of kinase regulation and provided new
templates for structure based design of selective inhibitors.
4. Strategies for the development of selective inhibitors
One of the most successful strategies for the development of
selective inhibitors is targeting of diverse inactive conformations of
kinases. These inactive states comprise the DFG-out state, in which
the conserved phosphate binding motif “DFG” changes conformation
opening a large allosteric binding pocket. This conformation is crucial
for the tight binding of the ﬁrst approved kinase inhibitor gleevec to
inactive ABL but the binding mode was only recognized long after this
drug had been developed [20], targeting the DFG out conformation
Fig. 2. Binding of Iodotubercidine to haspin and selectivity of the inhibitor. (A) Structural overview showing the structure of the haspin kinase domain in complex with
iodotubercidine (pdb: 2vuw). The atypical activation segment of the kinase this kinase is highlighted in blue. The active site shown in the detailed view in B is indicated by a dashed
square. (B) Detailed view of the haspin active site in complex with iodotubercidine. Residues interacting with the inhibitor are labelled and shown in stick representation. (C)
Selectivity proﬁle showing hits in a screen of 10 μM iodotubercidine against a representative set of 98 human kinases. Hits that showed Tm shifts of more than 10 °C, representing low
nm hits are highlighted by large red spheres, Tm shifts 10 °CNTmN6 °C (representing N100 nM to μM hits) are shown by smaller spheres and hits 6 °CNTmN4 °C (μM hits) are
indicated by very small spheres. Targets with Tm shifts smaller than 4 °C are not shown.
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selective kinase inhibitors. The inactive states of kinases are much
more diverse than the well conserved active state of kinases [6,21].
However, targeting the DFG out conformation per se does not
guaranty more favourable selectivity proﬁles and many unexpectedly
cross reacting targets have been identiﬁed for type II inhibitors as
well. Other strategies aim to target unique active site features, for
instance small residues located in the hinge gatekeeper position that
open an additional binding pocket. In addition, targeting allosteric
binding sites that are located outside the conserved ATP binding
pocket is an emerging strategy that has generated very selective
inhibitors [22,23].
Highly potent and selective ligands can also be developed using
organometallic inhibitors. Metal centres offer a large chemical
diversity by their ability to coordinate a wide variety of ligand
spheres. This property made it possible to design ligands that showed
outstanding shape complementarity to kinase active sites and that
bind with sub-nanomolar potency to the protein kinases PIM1 and
GSK3beta [24,25].
Finally, certain human ePKs have very diverse active sites and
share less than 25% homology with other kinase family members. The
diversity of the ATP site and the lack of certain motifs that are
otherwise highly conserved in ePKs makes the design of selective
inhibitors less challenging. A number of these diverse kinases have
interesting links to disease. One examples for such an atypical kinase
is haspin (haploid germ cell–speciﬁc nuclear protein kinase, encoded
by Germ cell-speciﬁc gene 2; Gsg2) [26]. Haspin lacks both the
conserved ATP/Mg2+ binding motif Asp-Phe-Gly (DFG), which is
replaced by Asp-Tyr-Thr (DYT), and the Ala-Pro-Glu (APE) motif
usually found at the C-terminus of the activation segment. In addition,haspin shares onlyweak sequence homologywith ePKs and contains a
highly divergent kinase domain with several unique inserts [27].
Haspin plays a key role duringmitosis and is vital for the maintenance
of chromosome cohesion. Depletion of haspin leads to a loss of
cohesin association, premature chromatid separation and the failure
of normal chromosome segregation [28–30]. Mitotic kinases have
been recognized as appealing targets for the development of anti-
mitotic drugs for cancer therapy. Although no direct link of haspin to
cancer has been established so far this kinase plays an important role
in the activation of the well-established oncology target Aurora B [31].
Inhibitors with reasonable selectivity proﬁles have been recently
identiﬁed by screening of a targeted chemical library. In particular the
inhibitor iodotubercidin cross-reacted only with a signiﬁcant tem-
perature shift with one other kinase (DYRK2) using a screening panel
of 98 kinases using differential scanning calorimetry (Fig. 2). The high
potency of iodotubercidin, its cell permeability and selectivity for
haspin makes this compound an interesting tool to elucidate haspin
function and it may serve as a good starting point for future inhibitor
development.
A number of large cross screening panels have been developed
recently that allow extensive proﬁling of kinase inhibitors [5,32–34].
However, the high cost of commercial selectivity screening usually
precludes frequent use of the established panels for academic
laboratories. Also only few large screening arrays are available to
laboratories that are interested in the development of selective kinase
inhibitors in academia [33,34]. Using the available reagents we started
also to provide selectivity data for a large number of kinase targets
using a differential scanning ﬂuorimetry assay format [35]. This large
body of structural and screening data can now be applied to
understand mechanisms of inhibitor cross reactivity. Emerging
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speciﬁcity include out of the “Box” inhibitors (e.g. allosteric Inhibitors,
regulatory domain and catalytic domain interfaces), utilising unique
binding modes, unusual active site features and atypical kinases that
attracted very little attention so far. In addition, non-human protein
kinases expressed in pathogens as essential genes may offer an
attractive strategy for treatment of infectious disease. These kinases
are often structurally very diverse and may contain unique active site
features that can be explored for selective inhibitor development
[36,37]. Inhibitors that bind outside the largely conserved ATP binding
pocket offer a promising strategy to improve selectivity. The allosteric
site modulates kinase activity and exhibit the highest degree of kinase
selectivity because they exploit binding sites and regulatory mechan-
isms that are unique to a particular kinase.
5. Conclusion
In recent years high throughput structure determination efforts
provided a large resource of structural and chemogenomic informa-
tion for the design of kinase inhibitors. Multiple structures deter-
mined in complex with different inhibitors locked kinase catalytic
domain structures in a variety of different conformations. Comparison
of these diverse conformational states provided insight into the
dynamic features of kinases and unravelled new mechanisms of
regulation.
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